Combined intervention with pioglitazone and n-3 fatty acids in metformin-treated type 2 diabetic patients: Improvement of lipid metabolism

Nutrition and Metabolism

Volumn 12, Issue 1, 2015, Pages

  Veleba, Jiri ^a   Kopecky, Jan ^a,b   Janovska, Petra ^b   Kuda, Ondrej ^b   Horakova, Olga ^b   Malinska, Hana ^a   Kazdova, Ludmila ^a   Oliyarnyk, Olena ^a   Skop, Vojtech ^a   Trnovska, Jaroslava ^a   Hajek, Milan ^a   Skoch, Antonin ^a   Flachs, Pavel ^b   Bardova, Kristina ^b   Rossmeisl, Martin ^b   Olza, Josune ^c   De Castro, Gabriela Salim ^c   Calder, Philip C ^c   Gardlo, Alzbeta ^b,d   Fiserova, Eva ^d   Jensen, Jørgen ^e   Bryhn, Morten ^f   Pelikanova, Terezie ^a   more..

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d PALACKÝ UNIVERSITY   (Czech Republic)

^e NORWEGIAN SCHOOL OF SPORT SCIENCES   (Norway)

^f Silentia AS   (Norway)

Author keywords

Docosahexaenoic acid; Eicosapentaenoic acid; Humans; Hyperinsulinemic euglycemic clamp; Indirect calorimetry; Meal test

Indexed keywords

ADIPONECTIN; CORN OIL; CYTOKINE; DOCOSAHEXAENOIC ACID; FATTY ACID; GLYCOSYLATED HEMOGLOBIN; ICOSAPENTAENOIC ACID; METFORMIN; PHOSPHOLIPID; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY WEIGHT; CALORIMETRY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; ENERGY METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPIDOMICS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84949219734     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/s12986-015-0047-9     Document Type: Article

References (39)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429-42.
2. American DA. Standards of medical care in diabetes - 2014. Diabetes Care. 2014;37 Suppl 1:S14-80.
3. Kim J, Kwak HJ, Cha JY, Jeong YS, Rhee SD, Kim KR, et al. Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction. J Biol Chem. 2014;289:23246-55.
4. Mirmiranpour H, Mousavizadeh M, Noshad S, Ghavami M, Ebadi M, Ghasemiesfe M, et al. Comparative effects of pioglitazone and metformin on oxidative stress markers in newly diagnosed type 2 diabetes patients: a randomized clinical trial. J Diabetes Complications. 2013;27:501-7.
5. Rodriguez A, Reviriego J, Karamanos V, del Canizo FJ, Vlachogiannis N, Drossinos V, et al. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study. Cardiovasc Diabetol. 2011;10:18.
6. Kus V, Flachs P, Kuda O, Bardova K, Janovska P, Svobodova M, et al. Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet. Plos One. 2011;6:e27126-7.
7. Kuda O, Jelenik T, Jilkova Z, Flachs P, Rossmeisl M, Hensler M, et al. n-3 Fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet. Diabetologia. 2009;52:941-51.
8. Yang J, Vallarino C, Bron M, Perez A, Liang H, Joseph G, et al. A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study. Curr Med Res Opin. 2014;30:2223-31.
9. Anagnostis P, Karras SN. Should we stop prescribing pioglitazone? Br J Clin Pharmacol. 2014;78:438-9.
10. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73-8.
11. Flachs P, Rossmeisl M, Kopecky J. The Effect of n-3 Fatty Acids on Glucose Homeostasis and Insulin Sensivity. Physiol Res. 2014;63:93-118.
12. Rakhshandehroo M, Hooiveld G, Muller M, Kersten S. Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. Plos One. 2009;4:e6796.
13. Kris-Etherton PM, Harris WS, Appel LJ, Association AHANCAH. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23:151-2.
14. Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome∗study. Hepatology. 2014;60:1211-21.
15. Mozaffarian D, Lemaitre RN, King IB, Song X, Huang H, Sacks FM, et al. Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study. Ann Intern Med. 2013;158:515-25.
16. Calder PC, Yaqoob P. Omega-3 (n-3) fatty acids, cardiovascular disease and stability of atherosclerotic plaques. Cell Mol Biol (Noisy-le-Grand). 2010;56:28-37.
17. Authors/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035-87.
18. Kromhout D, Geleijnse JM, de Goede J, Oude Griep LM, Mulder BJ, de Boer MJ, et al. n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care. 2011;34:2515-20.
19. Dangardt F, Chen Y, Gronowitz E, Dahlgren J, Friberg P, Strandvik B. High physiological omega-3 Fatty Acid supplementation affects muscle Fatty Acid composition and glucose and insulin homeostasis in obese adolescents. J Nutr Metab. 2012;2012:395757.
20. Horakova O, Medrikova D, van Schothorst EM, Bunschoten A, Flachs P, Kus V, et al. Preservation of Metabolic Flexibility in Skeletal Muscle by a Combined Use of n-3 PUFA and Rosiglitazone in Dietary Obese Mice. Plos One. 2012;7:e43764.
21. Pelikanova T, Smrckova I, Krizova J, Stribrna J, Lanska V. Effects of insulin and lipid emulsion on renal haemodynamics and renal sodium handling in IDDM patients. Diabetologia. 1996;39:1074-82.
22. Golay A, DeFronzo RA, Ferrannini E, Simonson DC, Thorin D, Acheson K, et al. Oxidative and non-oxidative glucose metabolism in non-obese type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1988;31:585-91.
23. Ejsing CS, Duchoslav E, Sampaio J, Simons K, Bonner R, Thiele C, et al. Automated identification and quantification of glycerophospholipid molecular species by multiple precursor ion scanning. Anal Chem. 2006;78:6202-14.
24. Kahleova H, Matoulek M, Malinska H, Oliyarnyk O, Kazdova L, Neskudla T, et al. Vegetarian diet improves insulin resistance and oxidative stress markers more than conventional diet in subjects with Type 2 diabetes. Diabet Med. 2011;28:549-59.
25. Jagadeesh B, Bharathi DV, Pankaj C, Narayana VS, Venkateswarulu V. Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;930:136-45.
26. Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. 2004;39:212-20.
27. Galgani JE, Moro C, Ravussin E. Metabolic flexibility and insulin resistance. Am J Physiol Endocrinol Metab. 2008;295:E1009-1017.
28. Riachi M, Himms-Hagen J, Harper ME. Percent relative cumulative frequency analysis in indirect calorimetry: application to studies of transgenic mice. Can J Physiol Pharmacol. 2004;82:1075-83.
29. Burdge GC, Calder PC. Plasma cytokine response during the postprandial period: a potential causal process in vascular disease? Br J Nutr. 2005;93:3-9.
30. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256:1-14.
31. Chan DC, Watts GF, Mori TA, Barrett PH, Beilin LJ, Redgrave TG. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest. 2002;32:429-36.
32. Flachs P, Rossmeisl M, Kuda O, Kopecky J. Stimulation of mitochondrial oxidative capacity in white fat independent of UCP1: A key to lean phenotype. Biochim Biophys Acta. 1831;2013:986-1003.
33. Wong AT, Chan DC, Ooi EM, Ng TW, Watts GF, Barrett PH. Omega-3 fatty acid ethyl ester supplementation decreases very-low-density lipoprotein triacylglycerol secretion in obese men. Clin Sci (Lond). 2013;125:45-51.
34. Miles EA, Rees D, Banerjee T, Cazzola R, Lewis S, Wood R, et al. Age-related increases in circulating inflammatory markers in men are independent of BMI, blood pressure and blood lipid concentrations. Atherosclerosis. 2008;196:298-305.
35. Hue L, Taegtmeyer H. The Randle cycle revisited: a new head for an old hat. Am J Physiol Endocrinol Metab. 2009;297:E578-91.
36. Williamson JR, Kreisberg RA, Felts PW. Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver. Proc Natl Acad Sci U S A. 1966;56:247-54.
37. Mostad IL, Bjerve KS, Basu S, Sutton P, Frayn KN, Grill V. Addition of n-3 fatty acids to a 4-hour lipid infusion does not affect insulin sensitivity, insulin secretion, or markers of oxidative stress in subjects with type 2 diabetes mellitus. Metabolism. 2009;58:1753-61.
38. Mostad IL, Bjerve KS, Bjorgaas MR, Lydersen S, Grill V. Effects of n-3 fatty acids in subjects with type 2 diabetes: reduction of insulin sensitivity and time-dependent alteration from carbohydrate to fat oxidation. Am J Clin Nutr. 2006;84:540-50.
39. Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58:493-504.